<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4226">
  <stage>Registered</stage>
  <submitdate>19/12/2013</submitdate>
  <approvaldate>19/12/2013</approvaldate>
  <nctid>NCT02020499</nctid>
  <trial_identification>
    <studytitle>Predictive Factors Study</studytitle>
    <scientifictitle>Non-interventional, Observational, Long Term Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel (ATG) Treatment in Patients With Acromegaly.</scientifictitle>
    <utrn />
    <trialacronym>TAPAS</trialacronym>
    <secondaryid>A-9B-52030-265</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acromegaly</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Somatuline Autogel® (lanreotide) 60, 90, 120 mg.

Acromegalic patients - Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)


Treatment: drugs: Somatuline Autogel® (lanreotide) 60, 90, 120 mg.
Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels from baseline</outcome>
      <timepoint>Baseline and 4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels from baseline</outcome>
      <timepoint>Baseline, 1 year and 3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of Acromegaly.

          -  Males and females aged 18 years and older.

          -  Signed informed consent (patient must give consent to the collection of retrospective
             data).

          -  Patients who have had surgery may enter the study 3 months post-surgery and evaluated
             for the duration of the study.

          -  With the intention to be treated with ATG (decision to prescribe ATG made prior to
             inclusion into the study) or already being treated with ATG.

          -  If already being treated with ATG:

        Previous ATG treatment maximum of 3 months. AND Minimum data available (demographic data,
        disease history including previous treatments, GH, IGF-1 levels at baseline and under
        treatment as applicable).

          -  Not receiving Dopamine Agonists or other medical therapy (Pegvisomant, or other
             somatostatin analogues) for the treatment or symptom control of acromegaly.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  The subject has had radiotherapy in the last 5 years.

          -  The subject has had surgery in the last 3 months.

          -  The subject has already been included in this study.

          -  Participation in an interventional trial, or receiving experimental drug.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>5</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>St Vincent's Hospital - Darlinghurst</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Royal Brisbane &amp; Women's Hospital - Herston</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>St Vincent's Hospital - Fitzroy</hospital>
    <hospital>The Austin Hospital - Heidelberg</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>4006 - Herston</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3084 - Heidelberg</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ipsen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a long term study to evaluate common therapeutic algorithms and possible predictive
      parameters for Somatuline Autogel treatment in patients with Acromegaly.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02020499</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sam Vohra</name>
      <address>Ipsen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>